SPHS Depositi SEC - Sophiris Bio Inc- Relazione annuale, dichiarazione di delega, prospetto informativo

Statistiche di base

CIK

1563855

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sophiris Bio Inc

SEC Filings (Chronological Order)

Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.

April 29, 2020	EX-10.1	Deferral Agreement to Loan and Security Agreement between the Registrant and Silicon Valley Bank dated April 22, 2020. Exhibit 10.1 Deferral Agreement Deferral Agreement Effective Date: April 22 , 20 20 Loan Agreement Date (use restated date if applicable): September 8 , 20 17 Borrower: Sophiris Bio Inc. ☑ If this box is checked, additional Borrowers ("Additional Borrowers") are listed in the Annex attached hereto (Borrower and such Additional Borrowers, collectively, "Borrower"). Loan Agreement: That certain Loan
April 29, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 23, 2020 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IRS
April 3, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 3, 2020 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IRS
March 31, 2020	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 30, 2020 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IRS
March 31, 2020	EX-16.1	Letter from PricewaterhouseCoopers LLP to the SEC, dated March 31, 2020, regarding the statements made in this Current Report on Form 8-K. Exhibit 16.1 March 31, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Sophiris Bio Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Sophiris Bio Inc. dated March 31, 2020. We agree with the statements concerning our Firm contai
March 11, 2020	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 10, 2020 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IRS
March 11, 2020	EX-99.1	Sophiris Bio Announces Nasdaq Delisting Exhibit 99.1 Sophiris Bio Announces Nasdaq Delisting SAN DIEGO and VANCOUVER, British Columbia, March 10, 2020 – Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that on March 10, 2020,
February 14, 2020	SC 13G/A	SPHS / Sophiris Bio, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 27, 2020	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 24, 2020 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (I
December 23, 2019	8-K	Current Report 8-K 1 sphs201912208k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other juris
December 13, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 9, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (I
December 13, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 10, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (
December 9, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 3, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (I
November 12, 2019	S-1	SPHS / Sophiris Bio, Inc. S-1 - Registration Statement - FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on November 12, 2019 Registration No.
November 8, 2019	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
November 7, 2019	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (I
November 7, 2019	EX-99.1	Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights Exhibit 99.1 Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, November 7, 2019 – Sophiris Bio Inc. (NASDAQ: SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported fi
October 22, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 21, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (I
October 8, 2019	8-K/A	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 27, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissio
September 12, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 6, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (
September 6, 2019	SC 13G	SPHS / Sophiris Bio, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
August 29, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 29, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IR
August 28, 2019	EX-4.1	Form of Pre-Funded Common Share Purchase Warrant Exhibit 4.1 EXHIBIT A-2 PRE-FUNDED COMMON SHARE PURCHASE WARRANT Sophiris Bio Inc. Warrant Shares: Initial Exercise Date: , 2019 Issue Date: , 2019 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time
August 28, 2019	EX-10.1	Form of Securities Purchase Agreement, dated August 26, 2019, by and between the Company and the Purchaser Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 26, 2019, between Sophiris Bio Inc., a British Columbia corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi
August 28, 2019	EX-99.1	Sophiris Bio Announces $4.0 Million Registered Direct Offering Exhibit 99.1 Sophiris Bio Announces $4.0 Million Registered Direct Offering SAN DIEGO and VANCOUVER, British Columbia, August 27, 2019 – Sophiris Bio Inc. (Nasdaq: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced
August 28, 2019	EX-4.2	Form of Series A Common Share Purchase Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
August 28, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 26, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IR
August 28, 2019	424B5	Sophiris Bio Inc. 3,355,000 Common Shares Pre-Funded Warrants to Purchase 1,978,334 Common Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333- 219887 PROSPECTUS SUPPLEMENT (To Prospectus dated August 30, 2017) Sophiris Bio Inc. 3,355,000 Common Shares Pre-Funded Warrants to Purchase 1,978,334 Common Shares Sophiris Bio Inc. is offering 3,355,000 common shares and pre-funded warrants to purchase 1,978,334 common shares, or the Pre-Funded Warrants, pursuant to this pr
August 9, 2019	EX-99.1	Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights Exhibit 99.1 Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, August 9, 2019 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urologica
August 9, 2019	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IRS
August 9, 2019	10-Q	SPHS / Sophiris Bio, Inc. 10-Q - Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
June 28, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 27, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IRS
June 7, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 4, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IRS E
May 9, 2019	10-Q	SPHS / Sophiris Bio, Inc. 10-Q Quarterly Report FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
May 9, 2019	EX-99.1	Sophiris Bio Reports First Quarter 2019 Financial Results Exhibit 99.1 Sophiris Bio Reports First Quarter 2019 Financial Results SAN DIEGO and VANCOUVER, British Columbia, May 9, 2019 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company,” “We” or “Sophiris”), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported f
May 9, 2019	EX-10.1	Development Agreement by and between Sophiris Bio Corp. and Vetter Pharma International GmbH, dated March 19, 2019. Exhibit 10.1 Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. DEVELOPMENT AGREEMENT by and between SOPHIRIS BIO CORP. and VETTER PHARMA INTERNATIONAL GMBH — ii — TABLE OF CONTENTS 1: DEFINITIONS 1 2: SERVICES 4 3: REPRESENTATIONS AND WARRANTIES BY CUST
May 9, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IRS Em
April 30, 2019	DEF 14A	SPHS / Sophiris Bio, Inc. DEF 14A FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 30, 2019	DEFA14A	SPHS / Sophiris Bio, Inc. DEFA14A FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 13, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 7, 2019 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IRS
March 13, 2019	EX-99.1	Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights Exhibit 99.1 Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company,” “We” or “Sophiris”), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of pa
March 13, 2019	10-K	SPHS / Sophiris Bio, Inc. FORM 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
January 3, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 31, 2018 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of incorporation) (Commis
December 17, 2018	EX-99.1	Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial Exhibit 99.1 Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial - Reiterates plans to move to Phase 3 with single administration of topsalysin SAN DIEGO and VANCOUVER, British Columbia, December 17, 2018 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-s
December 17, 2018	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 17, 2018 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (
December 7, 2018	424B5	Common Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-219887 PROSPECTUS SUPPLEMENT (To Prospectus dated August 30, 2017) $20,000,000 Common Shares We have entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to our common shares, no par value per share, offered by this prospectus supplement a
December 7, 2018	EX-10.1	Controlled Equity OfferingSM Sales Agreement dated December 7, 2018 by and among the Registrant and Cantor Fitzgerald & Co. Exhibit 10.1 Sophiris Bio Inc. Common Shares (no par value) Controlled Equity OfferingSM Sales Agreement December 7, 2018 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Sophiris Bio Inc., a corporation governed by the Business Corporations Act of British Columbia (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”),
December 7, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 7, 2018 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of incorporation) (Commissi
November 13, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 13, 2018 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (
November 13, 2018	EX-99.1	Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Exhibit 99.1 Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, November 13, 2018 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urologi
November 13, 2018	10-Q	SPHS / Sophiris Bio, Inc. FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
August 30, 2018	EX-99.1	Sophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial Previously reported patient death determined unlikely to be related to topsalysin Exhibit 99.1 Sophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial Previously reported patient death determined unlikely to be related to topsalysin SAN DIEGO and VANCOUVER, British Columbia, August 29, 2018 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage cli
August 30, 2018	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 29, 2018 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IR
August 14, 2018	EX-99.1	Sophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Exhibit 99.1 Sophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, August 14, 2018 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late stage clinical trials for the treatment of patients with urologic
August 14, 2018	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2018 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IR
August 14, 2018	10-Q	SPHS / Sophiris Bio, Inc. FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
June 28, 2018	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 sphs201806278k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 27, 2018 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdic
June 25, 2018	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 25, 2018 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IRS
June 25, 2018	EX-99.1	Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer Exhibit 99.1 Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer SAN DIEGO and VANCOUVER, British Columbia, June 25, 2018 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late stage clinical tri
May 14, 2018	EX-99.1	Sophiris Bio Reports First Quarter 2018 Financial Results and Key Corporate Highlights Exhibit 99.1 Sophiris Bio Reports First Quarter 2018 Financial Results and Key Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, May 14, 2018 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late stage clinical trials for the treatment of patients with urological dise
May 14, 2018	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2018 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
May 14, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2018 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IRS E
April 27, 2018	DEFA14A	SPHS / Sophiris Bio, Inc. FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the ☐ Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 27, 2018	DEF 14A	SPHS / Sophiris Bio, Inc. FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
March 21, 2018	10-K	SPHS / Sophiris Bio, Inc. FORM 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
March 21, 2018	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 21, 2018 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission File Number) (IRS
March 21, 2018	EX-99.1	Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate Highlights Exhibit 99.1 Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, March 21, 2018 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients wit
December 8, 2017	8-K	Current Report sphs201712088k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2017 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of inco
November 9, 2017	EX-99.1	Sophiris Bio Reports Third Quarter Financial Results and Key Corporate Highlights ex99945.htm Exhibit 99.1 Sophiris Bio Reports Third Quarter Financial Results and Key Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, November 9, 2017 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class pore-forming protein, in late-stage clinical trials for the treatment of patients with urolo
November 9, 2017	8-K	Results of Operations and Financial Condition sphs201711088k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2017 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commiss
November 9, 2017	EX-10.1	Loan and Security Agreement, dated September 8, 2017 by and among the Registrant, Sophiris Bio Corp., Sophiris Bio Holding Corp. and Silicon Valley Bank. Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of September 8, 2017 (the “Effective Date”) among SILICON VALLEY BANK, a California corporation (“Bank”), SOPHIRIS BIO INC., a corporation existing under the laws of the Province of British Columbia (“Canadian Borrower”), Sophiris Bio Corp., a Delaware corporation (“US Borrower Corp”), and Sophiri
November 9, 2017	EX-4.10	Common Share Purchase Warrant Issued to Silicon Valley Bank, dated September 8, 2017. Exhibit 4.10 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY,
November 9, 2017	10-Q	SPHS / Sophiris Bio, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
September 13, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant sphs201709128k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 8, 2017 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of inc
August 28, 2017	CORRESP	Sophiris Bio ESP sphs20170828corresp.htm Sophiris Bio Inc. 1258 Prospect Street La Jolla, CA 92037 USA August 28, 2017 Via EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Ada D. Sarmento RE: Sophiris Bio Inc. Registration Statement on Form S-3 Filed August 10, 2017 File No. 333-219887 Ladies and Gentlemen: Pursuant to Rule 461 under the
August 24, 2017	S-3/A	Sophiris Bio FORM S-3/A sphs20170822s3a.htm As filed with the Securities and Exchange Commission on August 24, 2017 Registration No. 333-219887 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHIRIS BIO INC. (Exact name of registrant as specified in its charter) British Columbia 98-1008712 (State or other jurisdi
August 10, 2017	S-3	Sophiris Bio FORM S-3 sphs20170802s3.htm As filed with the Securities and Exchange Commission on August 10, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHIRIS BIO INC. (Exact name of registrant as specified in its charter) British Columbia 98-1008712 (State or other jurisdiction of incorporation or
August 10, 2017	EX-4.9	SOPHIRIS BIO INC. ________, AS WARRANT AGENT FORM OF COMMON SHARE WARRANT AGREEMENT DATED AS OF [__], 20___ SOPHIRIS BIO INC. FORM OF COMMON SHARE WARRANT AGREEMENT EX-4.9 2 ex4-9.htm EXHIBIT 4.9 Exhibit 4.9 SOPHIRIS BIO INC. and , AS WARRANT AGENT FORM OF COMMON SHARE WARRANT AGREEMENT DATED AS OF [], 20 SOPHIRIS BIO INC. FORM OF COMMON SHARE WARRANT AGREEMENT Common Share Warrant Agreement (this “Agreement”), dated as of between Sophiris Bio Inc. (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of a
August 10, 2017	EX-4.10	Sophiris bio inc. ________, AS WARRANT AGENT FORM OF PREFERRED Share WARRANT AGREEMENT DATED AS OF [__], 20___ SOPHIRIS BIO INC. FORM OF PREFERRED Share WARRANT AGREEMENT EX-4.10 3 ex4-10.htm EXHIBIT 4.10 Exhibit 4.10 Sophiris bio inc. and , AS WARRANT AGENT FORM OF PREFERRED Share WARRANT AGREEMENT DATED AS OF [], 20 SOPHIRIS BIO INC. FORM OF PREFERRED Share WARRANT AGREEMENT Preferred Share Warrant Agreement (this “Agreement”), dated as of between Sophiris Bio Inc. (the “Company”), and , a [corporation] [national banking association] organized and existing under
August 10, 2017	EX-12.1	STATEMENT REGARDING COMPUTATION OF RATIOS (in thousands) ex12-1.htm Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIOS (in thousands) For the years ended December 31, For the six months ended June 30, 2012 2013 2014 2015 2016 2107 Earnings: Net loss $ (21,194 ) $ (11,149 ) $ (30,712 ) $ (14,197 ) $ (11,164 ) $ (2,010 ) Add: Fixed charges 2,069 1,380 767 725 408 18 Earnings as defined $ (19,125 ) $ (9,769 ) $ (29,945 ) $ (13,472 ) $ (10,756 ) $ (1,99
August 10, 2017	EX-99.1	Sophiris Bio Reports Second Quarter Financial Results and Key Corporate Highlights ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Second Quarter Financial Results and Key Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, August 10, 2017 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a late stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases, today reported financial results
August 10, 2017	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201708088k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2017 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissi
August 10, 2017	EX-3.2	Notice of Articles of the Registrant. Exhibit 3.2
August 10, 2017	10-Q	SPHS / Sophiris Bio, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
June 2, 2017	8-K	Current Report sphs201706018k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 30, 2017 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of incorpor
May 15, 2017	EX-99.1	Sophiris Bio Reports First Quarter Financial Results and Key Corporate Highlights ex99-1.htm Exhibit 99.1 Sophiris Bio Reports First Quarter Financial Results and Key Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, May 15, 2017 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a late stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases, today reported first quarter financia
May 15, 2017	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201705118k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2017 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission
May 15, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q sphs2017033110q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-
April 13, 2017	DEFA14A	Sophiris Bio FORM DEFA14A sphs20170411defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by R
April 13, 2017	DEF 14A	Sophiris Bio FORM DEF 14A sphs20170406def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru
March 27, 2017	EX-99.1	Sophiris Bio Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate Highlights ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate Highlights SAN DIEGO and VANCOUVER, British Columbia, March 27, 2017 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases, today reported
March 27, 2017	8-K	Results of Operations and Financial Condition sphs201703248k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 27, 2017 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of incorpo
March 27, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K sphs2016123110k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054
March 17, 2017	8-K	Current Report sphs201703178k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 15, 2017 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of incorp
February 14, 2017	SC 13G/A	SPHS / Sophiris Bio, Inc. / Boxer Capital, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* SOPHIRIS BIO INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 83578Q100 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
February 10, 2017	SC 13G/A	SPHS / Sophiris Bio, Inc. / CVI Investments, Inc. - SC 13G/A Passive Investment CUSIP No: 83578Q209 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Sophiris Bio Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 83578Q209 (CUSIP Number) December 31, 20
January 30, 2017	SC 13G/A	SPHS / Sophiris Bio, Inc. / Empery Asset Management, LP - EMPERY ASSET MANAGEMENT, LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sophiris Bio, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 83578Q209 (CUSIP Number) December 31, 2016 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sched
December 21, 2016	S-8	Sophiris Bio FORM S-8 sphs20161220s8.htm As filed with the Securities and Exchange Commission on December 21, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHIRIS BIO INC. (Exact name of registrant as specified in its charter) British Columbia 98-1008712 (State or other jurisdiction of incorporation o
December 9, 2016	8-K	Current Report sphs201612098k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 7, 2016 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of inco
November 9, 2016	8-K	Results of Operations and Financial Condition sphs201611098k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2016 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commiss
November 9, 2016	EX-99.1	Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business Highlights ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business Highlights SAN DIEGO and VANCOUVER, British Columbia, November 9, 2016 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three and nine months
November 9, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q sphs2016082310q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number:
October 14, 2016	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201610138k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 12, 2016 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commiss
August 26, 2016	SC 13G	SPHS / Sophiris Bio, Inc. / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 83578Q209 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Sophiris Bio Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 83578Q209 (CUSIP Number) August 23, 2016
August 26, 2016	SC 13G	SPHS / Sophiris Bio, Inc. / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 83578Q209 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Sophiris Bio Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 83578Q209 (CUSIP Number) August 23, 2016
August 23, 2016	EX-99.1	Sophiris Bio Announces Proposed Public Offering of Common Shares and Warrants ex99-1.htm Exhibit 99.1 Sophiris Bio Announces Proposed Public Offering of Common Shares and Warrants SAN DIEGO and VANCOUVER, British Columbia, Aug. 22, 2016 /PRNewswire/ ? Sophiris Bio Inc. (NASDAQ: SPHS) (?Sophiris?), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced that it intends to offer and sell, subject to market and other
August 23, 2016	EX-4.1	Form of Common Share Purchase Warrant Issued in connection with the Company’s August 2016 Financing. ex4-1.htm Exhibit 4.1 COMMON STOCK PURCHASE WARRANT sophiris bio inc. Warrant Shares: Initial Exercise Date: THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant? and the term ?Warrants? below refers to this Warrant and all other warrants to purchase Common Stock originally issued by the Company on the date hereof) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the
August 23, 2016	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201608228k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2016 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissio
August 23, 2016	EX-4.1	Form of Common Share Purchase Warrant Issued in connection with the Company’s August 2016 Financing. ex4-1.htm Exhibit 4.1 COMMON STOCK PURCHASE WARRANT sophiris bio inc. Warrant Shares: Initial Exercise Date: THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant? and the term ?Warrants? below refers to this Warrant and all other warrants to purchase Common Stock originally issued by the Company on the date hereof) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the
August 23, 2016	EX-99.2	Sophiris Bio Prices Public Offering of Common Shares and Warrants ex99-2.htm Exhibit 99.2 Sophiris Bio Prices Public Offering of Common Shares and Warrants SAN DIEGO and VANCOUVER, British Columbia, Aug. 23, 2016 /PRNewswire/ ? Sophiris Bio Inc. (NASDAQ: SPHS) (?Sophiris?), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced the pricing of an underwritten public offering of 6,500,000 of its common
August 23, 2016	EX-99.1	Sophiris Bio Announces Proposed Public Offering of Common Shares and Warrants ex99-1.htm Exhibit 99.1 Sophiris Bio Announces Proposed Public Offering of Common Shares and Warrants SAN DIEGO and VANCOUVER, British Columbia, Aug. 22, 2016 /PRNewswire/ ? Sophiris Bio Inc. (NASDAQ: SPHS) (?Sophiris?), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced that it intends to offer and sell, subject to market and other
August 23, 2016	EX-99.2	Sophiris Bio Prices Public Offering of Common Shares and Warrants ex99-2.htm Exhibit 99.2 Sophiris Bio Prices Public Offering of Common Shares and Warrants SAN DIEGO and VANCOUVER, British Columbia, Aug. 23, 2016 /PRNewswire/ ? Sophiris Bio Inc. (NASDAQ: SPHS) (?Sophiris?), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced the pricing of an underwritten public offering of 6,500,000 of its common
August 23, 2016	EX-1.1	6,500,000 Common Shares Warrants to Purchase 4,875,000 Common Shares SOPHIRIS BIO INC. PURCHASE AGREEMENT ex1-1.htm Exhibit 1.1 Execution Version 6,500,000 Common Shares and Warrants to Purchase 4,875,000 Common Shares SOPHIRIS BIO INC. PURCHASE AGREEMENT August 23, 2016 PIPER JAFFRAY & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Sophiris Bio Inc., a British
August 23, 2016	EX-1.1	6,500,000 Common Shares Warrants to Purchase 4,875,000 Common Shares SOPHIRIS BIO INC. PURCHASE AGREEMENT ex1-1.htm Exhibit 1.1 Execution Version 6,500,000 Common Shares and Warrants to Purchase 4,875,000 Common Shares SOPHIRIS BIO INC. PURCHASE AGREEMENT August 23, 2016 PIPER JAFFRAY & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Sophiris Bio Inc., a British
August 23, 2016	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201608228k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2016 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissio
August 23, 2016	424B5	Per Common Share and Accompanying Warrant sphs20160818424b5.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-198782 PROSPECTUS SUPPLEMENT (To Prospectus dated October 3, 2014) Sophiris Bio Inc. 6,500,000 Common Shares Warrants to Purchase up to 4,875,000 Common Shares ? Sophiris Bio Inc. is offering 6,500,000 common shares and warrants to purchase up to 4,875,000 common shares (and the common shares that are issuable from time to
August 23, 2016	424B5	Per Common Share and Accompanying Warrant sphs20160818424b5.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-198782 PROSPECTUS SUPPLEMENT (To Prospectus dated October 3, 2014) Sophiris Bio Inc. 6,500,000 Common Shares Warrants to Purchase up to 4,875,000 Common Shares ? Sophiris Bio Inc. is offering 6,500,000 common shares and warrants to purchase up to 4,875,000 common shares (and the common shares that are issuable from time to
August 22, 2016	424B5	Subject to Completion, dated August 22, 2016 sphs20160818424b5.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-198782 The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
August 22, 2016	424B5	Subject to Completion, dated August 22, 2016 sphs20160818424b5.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-198782 The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
August 22, 2016	8-K	Financial Statements and Exhibits, Other Events sphs201608188k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2016 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissio
August 22, 2016	EX-99.1	COMPANY OVERVIEW ex99-1.htm Exhibit 99.1 COMPANY OVERVIEW Overview We are a clinical-stage biopharmaceutical company focused on developing innovative products for the treatment of urological diseases. We are headquartered in San Diego, California and our common shares currently trade on The NASDAQ Capital Market. We are currently developing topsalysin (PRX302) as a treatment for localized low to intermediate risk
August 22, 2016	EX-99.1	COMPANY OVERVIEW ex99-1.htm Exhibit 99.1 COMPANY OVERVIEW Overview We are a clinical-stage biopharmaceutical company focused on developing innovative products for the treatment of urological diseases. We are headquartered in San Diego, California and our common shares currently trade on The NASDAQ Capital Market. We are currently developing topsalysin (PRX302) as a treatment for localized low to intermediate risk
August 9, 2016	EX-99.1	Sophiris Bio Reports Second Quarter 2016 Financial Results and Key Business Highlights ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Second Quarter 2016 Financial Results and Key Business Highlights SAN DIEGO and VANCOUVER, British Columbia, August 9, 2016 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three and six months e
August 9, 2016	EX-99.1	Sophiris Bio Reports Second Quarter 2016 Financial Results and Key Business Highlights ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Second Quarter 2016 Financial Results and Key Business Highlights SAN DIEGO and VANCOUVER, British Columbia, August 9, 2016 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three and six months e
August 9, 2016	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201608088k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2016 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissio
August 9, 2016	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201608088k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2016 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissio
August 9, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q sphs2016063010q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-3
June 10, 2016	8-K	Financial Statements and Exhibits sphs201606098k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 9, 2016 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission
June 10, 2016	EX-99.1	Sophiris Bio Reports Successful Results from Completed Phase 2a Study of Topsalysin in Localized Prostate Cancer Topsalysin successfully ablated tumor cells in patients with clinically significant localized disease ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Successful Results from Completed Phase 2a Study of Topsalysin in Localized Prostate Cancer Topsalysin successfully ablated tumor cells in patients with clinically significant localized disease Investor webcast scheduled for today at 2:00 p.m. Pacific Time SAN DIEGO and VANCOUVER, British Columbia, June 9, 2016 - Sophiris Bio Inc. (NASDAQ: SPHS) (the "C
June 3, 2016	S-8	Sophiris Bio FORM S-8 sphs20160531s8.htm As filed with the Securities and Exchange Commission on June 3, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHIRIS BIO INC. (Exact name of registrant as specified in its charter) British Columbia 98-1008712 (State or other jurisdiction of incorporation or org
June 1, 2016	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201605318k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 25, 2016 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of incorpor
May 24, 2016	SC 13G	SPHS / Sophiris Bio, Inc. / Empery Asset Management, LP - SOPHIRIS BIO, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sophiris Bio, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 83578Q209 (CUSIP Number) May 6, 2016 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13
May 16, 2016	EX-99.1	Sophiris Bio Reports First Quarter 2016 Financial Results and Key Business Highlights ex99-1.htm Exhibit 99.1 Sophiris Bio Reports First Quarter 2016 Financial Results and Key Business Highlights SAN DIEGO and VANCOUVER, British Columbia, May 16, 2016 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three months ended March
May 16, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q sphs2016033110q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-
May 16, 2016	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201605158k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 16, 2016 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission
May 10, 2016	EX-10.2	Form of Securities Purchase Agreement, dated May 6, 2016, by and between the Registrant and the Purchasers thereto. ex10-2.htm Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of May 6, 2016, between Sophiris Bio Inc., a British Columbia corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and
May 10, 2016	EX-10.1	Letter Agreement, dated May 6, 2016, by and between the Registrant and Roth Capital Partners, LLC. ex10-1.htm Exhibit 10.1 PLACEMENT AGENCY AGREEMENT May 6, 2016 Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 Ladies and Gentlemen: Sophiris Bio Inc., a British Columbia corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell, through the Roth Capital Partners, LLC (the ?Placement Agent?) as placement agent, securities
May 10, 2016	EX-99.1	Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering ex99-1.htm Exhibit 99.1 Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering SAN DIEGO and VANCOUVER, British Columbia, May 6, 2016 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that it is raising approximately $5 million at a price
May 10, 2016	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201605108k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2016 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission F
May 10, 2016	EX-4.1	Form of Common Share Purchase Warrant Issued in connection with the Company’s May 2016 Financing. ex4-1.htm Exhibit 4.1 COMMON STOCK PURCHASE WARRANT sophiris bio inc. Warrant Shares: Initial Exercise Date: THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initial Exercis
May 10, 2016	424B5	Sophiris Bio Inc. 3,571,428 Common Shares Warrants to Purchase 1,785,714 Common Shares sphs20160509424b5.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-198782 PROSPECTUS SUPPLEMENT (To Prospectus dated October 3, 2014) Sophiris Bio Inc. 3,571,428 Common Shares Warrants to Purchase 1,785,714 Common Shares We are offering 3,571,428 of our common shares and warrants to purchase up to 1,785,714 of our shares common shares (and the common shares that are issuable from time to
April 29, 2016	POS AM	Sophiris Bio FORM POS AM sphs20160427posam.htm As filed with the Securities and Exchange Commission on April 29, 2016 Registration No. 333-196331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sophiris Bio Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia 2834 98-1008712 (S
April 29, 2016	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201604278k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 25, 2016 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissio
April 25, 2016	DEF 14A	Sophiris Bio FORM DEF 14A sphs20160420def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru
April 8, 2016	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201604078k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 5, 2016 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of incorpor
March 29, 2016	S-8	Sophiris Bio FORM S-8 sphs20160322s8.htm As filed with the Securities and Exchange Commission on March 29, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHIRIS BIO INC. (Exact name of registrant as specified in its charter) British Columbia 98-1008712 (State or other jurisdiction of incorporation or o
March 29, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K sphs2015123110k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054
March 23, 2016	8-K	Results of Operations and Financial Condition sphs201603238k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 23, 2016 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissio
March 23, 2016	EX-99.1	Sophiris Bio Reports Fourth Quarter and Full Year 2015 Financial Results and Key Business Highlights ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Fourth Quarter and Full Year 2015 Financial Results and Key Business Highlights SAN DIEGO and VANCOUVER, British Columbia, March 23, 2016 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three mo
February 16, 2016	SC 13G/A	SPHS / Sophiris Bio, Inc. / Boxer Capital, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SOPHIRIS BIO INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 83578Q100 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
February 16, 2016	SC 13G/A	SPHS / Sophiris Bio, Inc. / Biotechnology Value Fund L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Sophiris Bio, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 83578Q209 (CUSIP Number) December 31, 2015 (
February 1, 2016	424B3	Prospectus Supplement No. 12 (to prospectus dated May 6, 2015) Sophiris Bio Inc. sphs20160128424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 12 (to prospectus dated May 6, 2015) Sophiris Bio Inc. This Prospectus Supplement No. 12 supplements and amends the prospectus dated May 6, 2015, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated May 15, 2015, Prospectus Supplement No. 2 thereto, dated May 29, 2015,
February 1, 2016	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201601278k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 28, 2016 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commiss
February 1, 2016	EX-99.1	Sophiris Bio Reports Encouraging Preliminary Data from Phase 2a Proof of Concept Study in Localized Prostate Cancer Investor webcast scheduled for today at 11:00 a.m. Pacific Time ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Encouraging Preliminary Data from Phase 2a Proof of Concept Study in Localized Prostate Cancer Investor webcast scheduled for today at 11:00 a.m. Pacific Time SAN DIEGO and VANCOUVER, British Columbia, January 28, 2016 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a biopharmaceutical company developing PRX302 (topsalysin) for the tre
November 30, 2015	424B3	Prospectus Supplement No. 11 (to prospectus dated May 6, 2015) Sophiris Bio Inc. sphs20151130424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 11 (to prospectus dated May 6, 2015) Sophiris Bio Inc. This Prospectus Supplement No. 11 supplements and amends the prospectus dated May 6, 2015, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated May 15, 2015, Prospectus Supplement No. 2 thereto, dated May 29, 2015,
November 30, 2015	8-K	Current Report sphs201511248k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 24, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commis
November 18, 2015	424B3	Prospectus Supplement No. 10 (to prospectus dated May 6, 2015) Sophiris Bio Inc. sphs20151117424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 10 (to prospectus dated May 6, 2015) Sophiris Bio Inc. This Prospectus Supplement No. 10 supplements and amends the prospectus dated May 6, 2015, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated May 15, 2015, Prospectus Supplement No. 2 thereto, dated May 29, 2015,
November 16, 2015	EX-99.1	Sophiris Bio Reports Third Quarter Financial Results and Business Highlights ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Third Quarter Financial Results and Business Highlights SAN DIEGO and VANCOUVER, British Columbia, November 16, 2015 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three and nine months ended S
November 16, 2015	8-K	Results of Operations and Financial Condition 8-K 1 sphs201511168k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 16, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other juris
November 16, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
November 12, 2015	424B3	Prospectus Supplement No. 9 (to prospectus dated May 6, 2015) Sophiris Bio Inc. sphs20151112424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 9 (to prospectus dated May 6, 2015) Sophiris Bio Inc. This Prospectus Supplement No. 9 supplements and amends the prospectus dated May 6, 2015, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated May 15, 2015, Prospectus Supplement No. 2 thereto, dated May 29, 2015, P
November 12, 2015	EX-99.1	Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint A single treatment with PRX302 (topsalysin) demonstrated a statistically significant improvement in BPH symptoms over a 12 month period ex99-1.htm Exhibit 99.1 Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint A single treatment with PRX302 (topsalysin) demonstrated a statistically significant improvement in BPH symptoms over a 12 month period SAN DIEGO and VANCOUVER, British Columbia ? November 10, 2015 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a biopharmaceutical company developing PRX302
November 12, 2015	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201511098k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commis
October 29, 2015	424B3	Prospectus Supplement No. 7 (to prospectus dated May 6, 2015) Sophiris Bio Inc. sphs20151029424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 7 (to prospectus dated May 6, 2015) Sophiris Bio Inc. This Prospectus Supplement No. 7 supplements and amends the prospectus dated May 6, 2015, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated May 15, 2015, Prospectus Supplement No. 2 thereto, dated May 29, 2015, P
October 29, 2015	424B3	Prospectus Supplement No. 8 (to prospectus dated May 6, 2015) Sophiris Bio Inc. sphs20151029b424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 8 (to prospectus dated May 6, 2015) Sophiris Bio Inc. This Prospectus Supplement No. 7 supplements and amends the prospectus dated May 6, 2015, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated May 15, 2015, Prospectus Supplement No. 2 thereto, dated May 29, 2015,
October 23, 2015	8-K	Current Report sphs201510228k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 22, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commiss
October 13, 2015	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201510128k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 7, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissi
August 24, 2015	424B3	Prospectus Supplement No. 6 (to prospectus dated May 6, 2015) Sophiris Bio Inc. sphs20150821d424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 6 (to prospectus dated May 6, 2015) Sophiris Bio Inc. This Prospectus Supplement No. 6 supplements and amends the prospectus dated May 6, 2015, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated May 15, 2015, Prospectus Supplement No. 2 thereto, dated May 29, 2015,
August 24, 2015	424B3	Prospectus Supplement No. 5 (to prospectus dated May 6, 2015) Sophiris Bio Inc. sphs20150821c424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 5 (to prospectus dated May 6, 2015) Sophiris Bio Inc. This Prospectus Supplement No. 5 supplements and amends the prospectus dated May 6, 2015, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated May 15, 2015, Prospectus Supplement No. 2 thereto, dated May 29, 2015,
August 24, 2015	424B3	Prospectus Supplement No. 3 (to prospectus dated May 6, 2015) Sophiris Bio Inc. sphs20150821424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 3 (to prospectus dated May 6, 2015) Sophiris Bio Inc. This Prospectus Supplement No. 3 supplements and amends the prospectus dated May 6, 2015, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated May 15, 2015 and Prospectus Supplement No. 2 thereto, dated May 29, 2015
August 24, 2015	424B3	Prospectus Supplement No. 4 (to prospectus dated May 6, 2015) Sophiris Bio Inc. sphs20150821b424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 4 (to prospectus dated May 6, 2015) Sophiris Bio Inc. This Prospectus Supplement No. 4 supplements and amends the prospectus dated May 6, 2015, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated May 15, 2015, Prospectus Supplement No. 2 thereto, dated May 29, 2015 a
August 21, 2015	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201508208k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 18, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissi
August 13, 2015	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201508128k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 13, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissi
August 13, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
August 13, 2015	EX-99.1	Sophiris Bio Reports Second Quarter Financial Results ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Second Quarter Financial Results SAN DIEGO and VANCOUVER, British Columbia, August 13, 2015 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three and six months ended June 30, 2015. ?In May we m
August 7, 2015	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201508068k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 3, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissio
June 15, 2015	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201506128k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 11, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission
May 29, 2015	424B3	Prospectus Supplement No. 2 (to prospectus dated May 6, 2015) Sophiris Bio Inc. sphs20150529424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 2 (to prospectus dated May 6, 2015) Sophiris Bio Inc. This Prospectus Supplement No. 2 supplements and amends the prospectus dated May 6, 2015, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated May 15, 2015, which we refer to collectively to as the Prospectus, relat
May 28, 2015	8-K	Submission of Matters to a Vote of Security Holders sphs201505278k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 27, 2015 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of incorpor
May 15, 2015	424B3	Prospectus Supplement No. 1 (to prospectus dated May 6, 2015) Sophiris Bio Inc. sphs20150514424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 1 (to prospectus dated May 6, 2015) Sophiris Bio Inc. This Prospectus Supplement No. 1 supplements and amends the prospectus dated May 6, 2015, or the Original Prospectus, relating to the sale of an aggregate of 3,409,629 of our common shares, no par value, by the selling shareholder identi
May 13, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
May 13, 2015	EX-99.1	Sophiris Bio Reports First Quarter Financial Results ex99-1.htm Exhibit 99.1 Sophiris Bio Reports First Quarter Financial Results SAN DIEGO and VANCOUVER, British Columbia, May 13, 2015 ? Sophiris Bio Inc. (NASDAQ: SPHS) (the ?Company? or ?Sophiris?), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three months ended March 31, 2015. ?Over the past quarter
May 13, 2015	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201505118k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 13, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission
May 6, 2015	424B7	3,409,629 Shares Sophiris Bio Inc. Common Shares sphs20150425posam.htm Filed Pursuant to Rule 424(b)(7) Registration No. 333-196331 PROSPECTUS 3,409,629 Shares Sophiris Bio Inc. Common Shares This prospectus relates to the sale of up to 3,409,629 of our common shares, no par value, by Aspire Capital Fund, LLC. Aspire Capital is also referred to in this prospectus as the selling shareholder. The prices at which the selling shareholder may sell th
April 27, 2015	POS AM	Sophiris Bio FORM POS AM sphs20150425posam.htm As filed with the Securities and Exchange Commission on April 27, 2014 Registration No. 333-196331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sophiris Bio Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia 2834 98-1008712 (S
April 27, 2015	EX-99.1	REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM sphs2014123110k.htm Exhibit 99.1 Item 8. Financial Statements and Supplementary Data REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Shareholders of Sophiris Bio Inc. In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations and comprehensive loss, of shareholders? equity (deficit) and of cash flows pres
April 27, 2015	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201504248k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 27, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissio
April 24, 2015	DEF 14A	Sophiris Bio FORM DEF 14A sphs20150331def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru
March 31, 2015	S-8	Sophiris Bio FORM S-8 sphs20150326s8.htm As filed with the Securities and Exchange Commission on March 31, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHIRIS BIO INC. (Exact name of registrant as specified in its charter) British Columbia 98-1008712 (State or other jurisdiction of incorporation or o
March 10, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
March 10, 2015	8-K	Sophiris Bio FORM 8-K (Current Report/Significant Event) sphs201503098k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 10, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissio
March 10, 2015	EX-99.1	Sophiris Bio Reports Fourth Quarter and Full Year Financial Results EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sophiris Bio Reports Fourth Quarter and Full Year Financial Results SAN DIEGO and VANCOUVER, British Columbia, March 10, 2015 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced financial results for the three months and y
February 17, 2015	SC 13G/A	SPHS / Sophiris Bio, Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Sophiris Bio Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 83578Q209 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch
February 13, 2015	SC 13G/A	SPHS / Sophiris Bio, Inc. / Invus Public Equities Advisors, Llc - 2015-023 13GA SOPHIRIS BIO Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SOPHIRIS BIO INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 83578Q209 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
February 12, 2015	424B3	Prospectus Supplement No. 5 (to prospectus dated June 23, 2014) Sophiris Bio Inc. sphs20150211424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 5 (to prospectus dated June 23, 2014) Sophiris Bio Inc. This Prospectus Supplement No. 5 supplements and amends the prospectus dated June 23, 2014, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated July 7, 2014, Prospectus Supplement No. 2 thereto, dated August 7, 2
February 12, 2015	SC 13G/A	SPHS / Sophiris Bio, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - SPHS AS OF 12/31/2014 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) SOPHIRIS BIO INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 83578Q209 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is
February 12, 2015	424B3	Prospectus Supplement No. 6 (to prospectus dated June 23, 2014) Sophiris Bio Inc. sphs20150211b424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 6 (to prospectus dated June 23, 2014) Sophiris Bio Inc. This Prospectus Supplement No. 6 supplements and amends the prospectus dated June 23, 2014, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated July 7, 2014, Prospectus Supplement No. 2 thereto, dated August 7,
February 6, 2015	8-K	Current Report sphs201502058k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2015 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of inco
January 30, 2015	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing sphs201501298k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 29, 2015 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commiss
January 26, 2015	424B3	Prospectus Supplement No. 3 (to prospectus dated June 23, 2014) Sophiris Bio Inc. sphs20150123424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 3 (to prospectus dated June 23, 2014) Sophiris Bio Inc. This Prospectus Supplement No. 3 supplements and amends the prospectus dated June 23, 2014, or the Original Prospectus, and Prospectus Supplement No. 2 thereto, dated July 7, 2014 and Prospectus Supplement No. 3 thereto, dated August 7
January 26, 2015	424B3	Prospectus Supplement No. 4 (to prospectus dated June 23, 2014) Sophiris Bio Inc. sphs20150123b424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 4 (to prospectus dated June 23, 2014) Sophiris Bio Inc. This Prospectus Supplement No. 4 supplements and amends the prospectus dated June 23, 2014, or the Original Prospectus, and Prospectus Supplement No. 2 thereto, dated July 7, 2014, Prospectus Supplement No. 3 thereto, dated August 7,
December 24, 2014	SC 13G	SPHS / Sophiris Bio, Inc. / Biotechnology Value Fund L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Sophiris Bio, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 83578Q209 (CUSIP Number) December 17, 2014 (D
December 24, 2014	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated December 24, 2014 with respect to the shares of Common Stock of Sophiris Bio, Inc. and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the
December 17, 2014	SC 13G/A	SPHS / Sophiris Bio, Inc. / Boxer Capital, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SOPHIRIS BIO INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 83578Q100 (CUSIP Number) December 15, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
December 15, 2014	EX-99	Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia San Diego and Vancouver, British Columbia, December 15, 2014 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of symptoms of benign prostatic hyperplasia (
December 15, 2014	8-K	Current Report sphs201412138k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 15, 2014 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of inco
November 12, 2014	EX-10	Officer Change in Control Severance Benefit Agreement by and between Peter T. Slover and the Company. Exhibit 10.3 OFFICER CHANGE IN CONTROL SEVERANCE BENEFIT AGREEMENT This OFFICER CHANGE IN CONTROL SEVERANCE BENEFIT AGREEMENT (the ?Agreement?) is made and entered into effective as of September 9, 2014, (the ?Effective Date?), by and between Sophiris Bio Inc., a British Columbia, Canada corporation (the ?Company?), and Peter Slover (the ?Officer?). The Company and the Officer are hereinafter coll
November 12, 2014	8-K	Results of Operations and Financial Condition sphs201411068k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 12, 2014 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commis
November 12, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table Of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
November 12, 2014	EX-10	Officer Change in Control Severance Benefit Agreement by and between Allison Hulme and the Registrant. Exhibit 10.2 OFFICER CHANGE IN CONTROL SEVERANCE BENEFIT AGREEMENT This OFFICER CHANGE IN CONTROL SEVERANCE BENEFIT AGREEMENT (the ?Agreement?) is made and entered into effective as of September 9, 2014, (the ?Effective Date?), by and between Sophiris Bio Inc., a British Columbia, Canada corporation (the ?Company?), and Allison Hulme (the ?Officer?). The Company and the Officer are hereinafter col
November 12, 2014	EX-10	Officer Change in Control Severance Benefit Agreement by and between Randall E. Woods and the Registrant. EX-10 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 OFFICER CHANGE IN CONTROL SEVERANCE BENEFIT AGREEMENT This OFFICER CHANGE IN CONTROL SEVERANCE BENEFIT AGREEMENT (the “Agreement”) is made and entered into effective as of September 9, 2014, (the “Effective Date”), by and between Sophiris Bio Inc., a British Columbia, Canada corporation (the “Company”), and Randall E. Woods (the “Officer”). The Company
November 12, 2014	EX-99	Sophiris Bio Reports Third Quarter Financial Results ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Third Quarter Financial Results San Diego and Vancouver, British Columbia, November 12, 2014 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized low to intermediate risk
October 14, 2014	AW	SPHS / Sophiris Bio, Inc. AW - - FORM AW sphs20141010aw.htm VIA EDGAR October 10, 2014 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Austin Stephenson Re: Sophiris Bio Inc. Application for Withdrawal of Post-Effective Amendment No. 1 to Form S-1 on Form S-3 File No. 333-196331 SEC Accession No. 0001437749-14-017130 Ladies and Gentlemen: Pursuant to Ru
October 3, 2014	424B3	PROSPECTUS Sophiris Bio Inc. Common shares Preferred shares sphs20140910s3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-198782 PROSPECTUS Sophiris Bio Inc. $100,000,000 Common shares Preferred shares Warrants From time to time, we may offer up to $100,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchan
September 16, 2014	EX-4	Sophiris bio inc. ________, AS WARRANT AGENT FORM OF PREFERRED Share WARRANT AGREEMENT DATED AS OF [__], 20___ SOPHIRIS BIO INC. FORM OF PREFERRED Share WARRANT AGREEMENT EX-4 3 ex4-17.htm EXHIBIT 4.17 Exhibit 4.17 Sophiris bio inc. and , AS WARRANT AGENT FORM OF PREFERRED Share WARRANT AGREEMENT DATED AS OF [], 20 SOPHIRIS BIO INC. FORM OF PREFERRED Share WARRANT AGREEMENT Preferred Share Warrant Agreement (this “Agreement”), dated as of between Sophiris Bio Inc. (the “Company”), and , a [corporation] [national banking association] organized and existing under the
September 16, 2014	POS AM	SPHS / Sophiris Bio, Inc. POS AM - - FORM POS AM sphs20140911posam.htm As filed with the Securities and Exchange Commission on September 16, 2014 Registration No. 333-196331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sophiris Bio Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia 28
September 16, 2014	EX-12	STATEMENT REGARDING COMPUTATION OF RATIOS (in thousands) EX-12 5 ex12-1.htm EXHIBIT 12.1 Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIOS (in thousands) For the years ended December 31, For the six months ended June 30, 2010 2011 2012 2013 2014 Earnings: Net loss $ (4,412 ) $ (14,201 ) $ (21,194 ) $ (11,149 ) $ (17,209 ) Add: Fixed charges 51 1,001 2,069 1,380 401 Earnings as defined $ (4,361 ) $ (13,200 ) $ (19,125 ) $ (9,769 ) $ (16,808 ) Fixed
September 16, 2014	EX-4	SOPHIRIS BIO INC. ________, AS WARRANT AGENT FORM OF COMMON SHARE WARRANT AGREEMENT DATED AS OF [__], 20___ SOPHIRIS BIO INC. FORM OF COMMON SHARE WARRANT AGREEMENT EX-4 2 ex4-16.htm EXHIBIT 4.16 Exhibit 4.16 SOPHIRIS BIO INC. and , AS WARRANT AGENT FORM OF COMMON SHARE WARRANT AGREEMENT DATED AS OF [], 20 SOPHIRIS BIO INC. FORM OF COMMON SHARE WARRANT AGREEMENT Common Share Warrant Agreement (this “Agreement”), dated as of between Sophiris Bio Inc. (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of
September 16, 2014	S-3	SPHS / Sophiris Bio, Inc. S-3 - - FORM S-3 sphs20140910s3.htm As filed with the Securities and Exchange Commission on September 16, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHIRIS BIO INC. (Exact name of registrant as specified in its charter) British Columbia 98-1008712 (State or other jurisdiction of incorporation
September 15, 2014	8-K	Current Report sphs201409108k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 9, 2014 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commis
August 7, 2014	EX-4	Common Share Purchase Warrant Issued to Oxford Finance LLC dated June 30, 2014. EX-4 3 ex4-11.htm EXHIBIT 4.11 Exhibit 4.11 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF L
August 7, 2014	EX-99	Sophiris Bio Reports Second Quarter Financial Results and Key Operational and Financial Highlights ex99-1.htm Exhibit 99.1 Sophiris Bio Reports Second Quarter Financial Results and Key Operational and Financial Highlights San Diego and Vancouver, British Columbia, August 7, 2014 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the trea
August 7, 2014	8-K	Results of Operations and Financial Condition sphs201407298k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2014 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commissio
August 7, 2014	424B3	Prospectus Supplement No. 2 (to prospectus dated June 23, 2014) Sophiris Bio Inc. sphs2014072510q.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 2 (to prospectus dated June 23, 2014) Sophiris Bio Inc. This Prospectus Supplement No. 2 supplements and amends the prospectus dated June 23, 2014, or the Original Prospectus, and Prospectus Supplement No. 1 thereto, dated July 7, 2014, which we refer collectively to as the Prospectus, relati
August 7, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table Of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
August 7, 2014	EX-4	Common Share Purchase Warrant Issued to Oxford Finance LLC dated June 30, 2014. Exhibit 4.10 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTA
August 7, 2014	EX-10	LOAN AND SECURITY AGREEMENT Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this ?Agreement?) dated as of June 30, 2014 (the ?Effective Date?) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (i
July 7, 2014	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant sphs201407028k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2014 Date of Report (Date of earliest event reported) Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction (Commission
July 7, 2014	424B3	Prospectus Supplement No. 1 (to prospectus dated June 23, 2014) Sophiris Bio Inc. sphs20140707424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-196331 Prospectus Supplement No. 1 (to prospectus dated June 23, 2014) Sophiris Bio Inc. This Prospectus Supplement No. 1 supplements and amends the prospectus dated June 23, 2013, or the Original Prospectus, relating to the sale of an aggregate of 3,409,629 of our common shares, no par value, by the selling shareholder id
June 24, 2014	424B7	3,409,629 Shares Sophiris Bio Inc. Common Shares sphs20140523s1.htm Table Of Contents Filed pursuant to Rule 424(b)(7) Registration No. 333-196331 PROSPECTUS 3,409,629 Shares Sophiris Bio Inc. Common Shares This prospectus relates to the sale of up to 3,409,629 of our common shares, no par value, by Aspire Capital Fund, LLC. Aspire Capital is also referred to in this prospectus as the selling shareholder. The prices at which the selling sharehol
June 18, 2014	S-1/A	- FORM S-1/A sphs20140523s1.htm Table Of Contents As filed with the Securities and Exchange Commission on June 18, 2014 Registration No. 333-196331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A AMENDMENT No. 1 to REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sophiris Bio Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia 2834 98-1008712 (
June 2, 2014	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K sphs201406028k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 29, 2014 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction of incorpor
May 28, 2014	S-1	Registration Statement - FORM S-1 sphs20140523s1.htm Table Of Contents As filed with the Securities and Exchange Commission on May 28, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sophiris Bio Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia 2834 98-1008712 (State or Other Jurisdiction
May 19, 2014	EX-10.1	COMMON STOCK PURCHASE AGREEMENT EX-10.1 EXECUTION COPY COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of May 16, 2014, by and between SOPHIRIS BIO INC., a British Columbia corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof. WHEREA
May 19, 2014	EX-99.1	Sophiris Enters into Common Stock Purchase Agreement with Aspire Capital to Support Proof of Concept Study of PRX302 in Prostate Cancer EX-99.1 Sophiris Enters into Common Stock Purchase Agreement with Aspire Capital to Support Proof of Concept Study of PRX302 in Prostate Cancer San Diego and Vancouver, British Columbia, May 19, 2014 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing treatments for urologic diseases, today announced it has entered into a common stock purchase a
May 19, 2014	EX-4.1	Registration Rights Agreement, dated May 16, 2014 by and between the Company and Aspire Capital Fund, LLC. EX-4.1 EXECUTION COPY REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 16, 2014, by and between SOPHIRIS BIO INC., a British Columbia corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall h
May 19, 2014	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - LIVE FILING Sophiris Bio Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2014 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction
May 13, 2014	EX-99.1	Sophiris Bio Reports First Quarter Financial Results EX-99.1 Sophiris Bio Reports First Quarter Financial Results San Diego and Vancouver, British Columbia, May 13, 2014 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today announced financial results and recent key operational hig
May 13, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
May 13, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - LIVE FILING Sophiris Bio Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2014 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdiction
April 7, 2014	DEF 14A	- DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
March 27, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - LIVE FILING Sophiris Bio Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 26, 2014 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdictio
March 25, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - LIVE FILING Sophiris Bio Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 19, 2014 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdictio
March 14, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-36054 Sophiris Bio Inc.
March 13, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 htm49454.htm LIVE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2014 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdicti
March 13, 2014	EX-99.1	Sophiris Bio Reports Fourth Quarter and Full Year 2013 Financial Results and Key Operational Highlights EX-99.1 Sophiris Bio Reports Fourth Quarter and Full Year 2013 Financial Results and Key Operational Highlights San Diego and Vancouver, British Columbia, March 13, 2014 – Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate, today annou
February 18, 2014	EX-10.1	Omnibus Amendment to Warrants to Purchase Common Shares dated February 14, 2014 by and between the Company and Oxford Finance LLC. EX-10.1 SOPHIRIS BIO INC. OMNIBUS AMENDMENT TO WARRANTS TO PURCHASE COMMON SHARES This Omnibus Amendment to Warrants to Purchase Common Shares (this “Agreement”) is made as of February 14, 2014, by and among Sophiris Bio Inc., a corporation amalgamated under the Business Corporations Act (British Columbia), f/k/a Protox Therapeutics Inc. (the “Company”), and Oxford Finance LLC a [Delaware] limited
February 18, 2014	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - LIVE FILING Sophiris Bio Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2014 Sophiris Bio Inc. (Exact name of registrant as specified in its charter) British Columbia 001-36054 98-1008712 (State or other jurisdic
February 14, 2014	SC 13G/A	SPHS / Sophiris Bio, Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sophiris Bio Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 83578Q209 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch
February 10, 2014	SC 13G	SPHS / Sophiris Bio, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - SPHS AS OF 12/31/2013 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SOPHIRIS BIO INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 83578Q209 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is

SPHS / Sophiris Bio Inc - Depositi SEC, Relazione annuale, dichiarazione di delega

Statistiche di base

SEC Filings

SEC Filings (Chronological Order)